ORGANON & CO Stock Price, News & Analysis

Organon (NYSE: OGN) has announced an $8 million strategic investment in Claria Medical, a company developing a medical device aimed at enhancing laparoscopic hysterectomy procedures. This investment includes an option for Organon to acquire Claria Medical. The Claria System is designed to improve safety and efficiency in hysterectomy surgeries and has been accepted into the FDA’s Safer Technologies Program. This move underscores Organon’s commitment to innovation in women’s healthcare.

Organon (NYSE: OGN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10th, 2023, at 7:30 a.m. PT. CEO Kevin Ali and CFO Matthew Walsh will engage in a fireside chat, accessible via a live audio webcast. This event underscores Organon's commitment to women's health with over 60 products aimed at improving health outcomes. The company, headquartered in Jersey City, New Jersey, is focused on innovation and collaboration in the biopharmaceutical sector.

Organon (NYSE: OGN) announced the appointment of Kirke Weaver as General Counsel and Corporate Secretary, effective January 1, 2023. Mr. Weaver, who was previously the interim head since July 2022, brings nearly 20 years of pharmaceutical experience, including key roles at Merck. His leadership is expected to further Organon's commitment to women’s health while enhancing its ethical operations. The company aims for continued growth through innovation and collaboration in the healthcare sector.

Organon (NYSE: OGN) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 9:00 a.m. EST. The chat will feature CEO Kevin Ali and CFO Matthew Walsh. Interested parties can listen to the live webcast via this link. Organon focuses on women's health with a diverse portfolio of over 60 medicines and products, supported by a robust cash flow, aiming for innovation and growth.

Organon reported third quarter 2022 revenues of $1,537 million, a 4% decline year-over-year. Diluted EPS from continuing operations was $0.89, down 30% from the previous year. Adjusted EBITDA stood at $546 million, down 11% year-over-year, reflecting higher costs and R&D expenditures. The women's health segment grew by 19%, while established brands saw a 11% decline. The company declared a quarterly dividend of $0.28 per share. Full year revenue guidance was narrowed to $6.1 billion to $6.2 billion.

Organon (NYSE: OGN) will announce its third quarter 2022 financial results on November 3, 2022, before a conference call at 8:30 a.m. EDT. The event can be accessed via a webcast on the company’s website, with a replay available shortly after. Organon focuses on improving women’s health and has a diverse portfolio of over 60 products, supported by strong cash flows. With a significant global presence, the company aims to expand its biosimilars business and collaborate with biopharmaceutical innovators.

Samsung Bioepis and Organon announced FDA approval for HADLIMA™ (adalimumab-bwwd), a citrate-free, high-concentration formulation of the adalimumab biosimilar referencing HUMIRA®. It will be available in pre-filled syringes and autoinjectors, enhancing treatment options for patients with chronic autoimmune diseases. This high-concentration version builds on the previous approval of a 50 mg/mL formulation in July 2019. The launch is expected on or after July 1, 2023, aiming to provide a more affordable alternative to the currently high-cost adalimumab in the U.S.

Organon (NYSE: OGN) reported Q2 2022 revenues of $1,585 million, a 1% decrease year-over-year but a 5% rise when excluding foreign currency impacts. The company recorded diluted EPS of $0.92 and adjusted EPS of $1.25, which faced a $0.30 negative impact due to acquired IPR&D costs. Adjusted EBITDA was $512 million with a margin of 32.3%. The board declared a quarterly dividend of $0.28 per share. The full-year revenue guidance has been updated to a range of $6.1 billion to $6.3 billion, reflecting ongoing foreign currency challenges.

Organon (NYSE: OGN) announced a research collaboration and exclusive license agreement with Cirqle Biomedical to develop a novel non-hormonal contraceptive. This investigational candidate aims to address the unmet needs of women seeking non-hormonal options. Organon will obtain exclusive rights to develop and commercialize the product, with Cirqle receiving a $10 million upfront payment and potential milestone payments of up to $360 million. The collaboration aligns with Organon’s focus on innovation in women’s health, as highlighted by its commitment to new contraceptive solutions.